ArticleJAMIA open2023
A global federated real-world data and analytics platform for research.
Article in JAMIA open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 431 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Early GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-On Strategies in Adults With Obesity, Type 2 Diabetes, Cardiovascular-Kidney-Metabolic Syndrome Stage 2-3, and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Target Trial Emulation
Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes: A Target Trial Emulation
Who cites it
431 citing papers in PubMed.
- Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation.Frontiers in endocrinology · 2026Trial
- Choosing real-world data for clinical and epidemiological research: methodological lessons from NHIRD and TriNetX-A narrative review.Annals of medicine · 2026Review
- Disease-specific safety and efficacy of DOACs vs LMWH for CAT in patients with brain metastases: a real-world analysis.Blood vessels, thrombosis & hemostasis · 2026Article
- Natriuretic peptides are integral in reclassifying heart failure stage and risk.Heart and vessels · 2026Article
- Big data: from signal to action.Proceedings (Baylor University. Medical Center) · 2026Article
- Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study.Alimentary pharmacology & therapeutics · 2026Article
- Retrospective analysis of preventable procedural adverse events (ICD-10 Y62-Y69) in the TriNetX network: a multiregional study before, during and after the COVID-19 pandemic.BMJ quality & safety · 2026Article
- Post-transplant diabetes mellitus requiring insulin identifies high-risk outcomes after solid organ transplantation.The Journal of clinical endocrinology and metabolism · 2026Article
- GLP-1 Receptor Agonists Are Associated With Lower Early Revision Risk Compared to Bariatric Surgery Following Total Hip Arthroplasty: A Retrospective Cohort Study.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2026Article
- Effectiveness and safety of cefazolin vs antistaphylococcal penicillins for methicillin-susceptibleAntimicrobial agents and chemotherapy · 2026Observational
- Article
- Obese Patients Undergoing Implant-based Breast Reconstruction: A Propensity Score-Matched Analysis.Plastic and reconstructive surgery. Global open · 2026Article
- TriNetX LATAM Collaborative Network, an EHR Data Source in Latin America.Pharmacoepidemiology and drug safety · 2026Article
- Assessment of Major Adverse Cardiovascular Event Across Diverse Racial Groups of Psoriasis Patients on Biologic Therapy: A Retrospective Cohort Study.The Journal of dermatology · 2026Article
- GLP-1 Receptor Agonists and Risk of Skin Cancer in Adults With Type 2 Diabetes: A Target Trial Emulation.Diabetes, obesity & metabolism · 2026Article
- Trends in diagnosis of amyloid kidney disease in people who inject drugs (PWID).Preventive medicine reports · 2026Article
- Immortal Time Bias Compromises Conclusions Regarding SGLT2 Inhibitor Use in Diabetic Prostate Cancer Patients on Hormone Therapy.Cardiovascular drugs and therapy · 2026Article
- Epidemiological Studies on Type 2 Diabetes Using the German Disease Analyser Database: A Narrative Review.Diabetes, obesity & metabolism · 2026Review
- Meniere's Disease and Migraine: Effect of Migraine Medications on Symptoms of Meniere's Disease.The Laryngoscope · 2026Article
- Treatment patterns and comparative clinical outcomes of ADHD medications in adolescents and young adults with comorbid major depressive disorder.Journal of affective disorders · 2026Article
371 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This article describes a scalable, performant, sustainable global network of electronic health record data for biomedical and clinical research. Materials and Methods: TriNetX has created a technology platform characterized by a conservative security and governance model that facilitates collaboration and cooperation between industry participants, such as pharmaceutical companies and contract research organizations, and academic and community-based healthcare organizations (HCOs). HCOs participate on the network in return for access to a suite of analytics capabilities, large networks of de-identified data, and more sponsored trial opportunities. Industry participants provide the financial resources to support, expand, and improve the technology platform in return for access to network data, which provides increased efficiencies in clinical trial design and deployment. Results: TriNetX is a growing global network, expanding from 55 HCOs and 7 countries in 2017 to over 220 HCOs and 30 countries in 2022. Over 19 000 sponsored clinical trial opportunities have been initiated through the TriNetX network. There have been over 350 peer-reviewed scientific publications based on the network's data. Conclusions: The continued growth of the TriNetX network and its yield of clinical trial collaborations and published studies indicates that this academic-industry structure is a safe, proven, sustainable path for building and maintaining research-centric data networks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.